Skip to main content

Table 1 Patient characteristics

From: Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma

  Luminal IDC (n = 1661) Luminal ILC (n = 104) (n = 104)  
  n % n % P-value
Median follow-up time(months) 53 49.5  
Age(years)
 Median 53 53  
  < 50 678 40 44 42  
50 982 59 60 57 0.768
Menopause status
 Pre 812 48 52 50  
 Post 844 50 50 48 0.703
Histological grade
 1 486 29 68 65  
 2 875 52 26 25  
 3 248 14 2 1 <0.001
Tumor size
 T1 1174 70 57 54  
 T2 422 25 40 38  
 T3 63 3 7 6 0.002
ER(Allred score)
 3 19 1 0 0  
 4 31 2 0 0  
 5 30 2 1 1  
 6 62 4 5 5  
 7 246 15 15 14  
 8 1273 76 83 80 0.575
HER2 status
 0 439 26 25 24  
 1 995 60 67 64  
 2(FISH-) 227 14 12 12 0.682
Lymph node status
 Positive 489 29 34 32  
 Negative 1021 61 61 58 0.492
Initial surgical treatment      
 BCS 779 47 41 39  
 Mastectomy 882 53 63 61 0.007
 Positive margins 38 2.2 7 6.7 0.016
Endocrine therapy
 Yes 1424 85 99 95  
 No 231 13 5 4 0.008
Chemotherapy
 Yes 672 40 44 42  
 No 982 59 60 57 0.735
  1. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, FISH fluorescent in situ hybridization, BCS breast conserving surgery